Leprosy [Hansen's disease]
Conditions
Interventions
Contacts of patients with leprosy under the age of fifteen will be included in the study. The contacts will receive a single supervised dose of rifampicin. In this type of study, all patients receive
Drug
D03.633.400.811.700
Sponsors
Universidade de Cuiabá
Universidade Federal de Mato Grosso
Universidade do Estado de Mato Grosso
Universidade Federal de Juiz de Fora
Instituto Oswaldo Cruz
Eligibility
Age
5 Years to 15 Years
Inclusion criteria
Inclusion criteria: Individuals younger than 15 years (5 years to 14 years, 11 months and 29 days); household contacts of new leprosy cases diagnosed and registered in the National Notification of Injury Information System (SINAN/MT) in 2018 (treatment or treatment virgin) up to 4 weeks of MDT use) of both sexes; who resided or resided within five years before/during the diagnosis of the index case.
Exclusion criteria
Exclusion criteria: It is those who refuse to undergo the clinical examination; who are diagnosed with leprosy during the examination; those who have a history of hypersensitivity after the previous dose of the vaccine or any component of the vaccine; pregnant women, patients receiving high dose corticosteroids ( 2 mg/kg/day for children up to 10 kg or 20 mg/kg/day for individuals over 10 kg) for a period of more than two weeks; patients taking other immunosuppressive therapies (antineoplastic chemotherapy, radiotherapy, among others).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Analyze the SDR strategy and BCG vaccine immunoprophylaxis using the Enzyme-Linked Immunosorbent Assay Immunosorbent Assay (ELISA) for detection of anti-NDO-LID antibodies and serum concentration - IFN-gamma in contacts under the age of fifteen, of multibacillary cases. The findings are expected to indicate a seroconversion of serological titers and increased immune response after intervention as a protective factor against the disease. | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the clinical manifestations of the disease, adverse events and the level of acceptability of the strategy; ;To analyze the variables regarding sociodemographic, cohabitational, clinical / epidemiological characteristics, consanguineous condition, characteristic of the index case, time of breastfeeding and serological test response. | — |
Countries
Brazil
Contacts
Public ContactCamila;Omar Sato;Espinosa Domínguez
Universidade Federal de Mato Grosso;Universidade do Estado de Mato Grosso
Outcome results
None listed